文献速递肺外科

KEYNOTE-671中围术期帕博利珠单抗治疗患者临床特征与手术结局

Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671.
PubMed 文献 · Ann Thorac Surg · 2025-11-05

KEYNOTE-671研究显示,可切除II-IIIB(N2)期NSCLC患者接受新辅助帕博利珠单抗联合化疗后手术及辅助帕博利珠单抗,手术率82.1%,R0切除率92.0%,手术延迟4.9%,术后30天内手术相关死亡6例,未对手术结局产生不利影响。

要点

  • 新辅助帕博利珠单抗未增加手术延迟或术后死亡风险。
  • 帕博利珠单抗组R0切除率数值上更高(92.0% vs 84.2%)。
  • 各手术相关亚组中帕博利珠单抗均改善无事件生存。

核心结论

  • 新辅助帕博利珠单抗未对早期NSCLC手术结局产生不利影响,数值上提高R0切除率,并在手术相关亚组中改善EFS。

研究设计与样本

  • III期KEYNOTE-671研究(NCT03425643),397例随机至帕博利珠单抗组,400例至安慰剂组。

主要发现

  • 帕博利珠单抗组325例(82.1%)和安慰剂组317例(79.4%)接受手术。
  • 手术延迟发生率帕博利珠单抗组4.9%,安慰剂组7.6%。
  • 淋巴结降期率帕博利珠单抗组38.9%,安慰剂组28.4%。
  • 肺叶切除率帕博利珠单抗组78.8%,安慰剂组75.1%。
  • R0切除率帕博利珠单抗组92.0%,安慰剂组84.2%。

关键数值与推荐

  • 新辅助帕博利珠单抗200 mg或安慰剂联合顺铂为基础的化疗,每3周4周期,术后辅助帕博利珠单抗或安慰剂13周期。
  • 手术于首剂新辅助治疗后≤20周(完成4周期)或末剂后4-8周(1-3周期)进行,超出定义为手术延迟。
  • 辅助治疗于术后4-12周开始。

临床怎么用

  • 围术期帕博利珠单抗联合化疗可作为可切除II-IIIB(N2)期NSCLC的新辅助及辅助治疗选择。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase 3 KEYNOTE-671 study (NCT03425643) demonstrated significantly improved event-free survival (EFS) and overall survival with neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant pembrolizumab vs neoadjuvant chemotherapy and surgery for early-stage non-small cell lung cancer (NSCLC). We describe participant characteristics, surgical outcomes, and EFS in surgically relevant subgroups. METHODS: Participants with untreated, resectable, stage II-IIIB (N2) NSCLC were randomized 1:1 to neoadjuvant pembrolizumab 200 mg or placebo plus cisplatin-based chemotherapy every 3 weeks for 4 cycles, then surgery and adjuvant pembrolizumab or placebo for 13 cycles. Surgery was performed ≤20 weeks after first neoadjuvant dose (if 4 cycles of neoadjuvant therapy) or 4-8 weeks after last neoadjuvant dose (1-3 cycles); surgery beyond this was considered surgical delay. Adjuvant therapy began 4-12 weeks after surgery. EFS was assessed in the surgical population. RESULTS: Of 397 participants randomized to pembrolizumab and 400 to placebo, 325 (82.1%) and 317 (79.4%), respectively, underwent surgery. At data cutoff (July 10, 2023), 4.9% (pembrolizumab) and 7.6% (placebo) of participants experienced surgical delay; 38.9% and 28.4%, respectively, experienced nodal downstaging; 78.8% and 75.1% underwent lobectomy; and 92.0% and 84.2% had R0 resections. Pembrolizumab improved EFS irrespective of disease stage, nodal status, and type of surgery vs chemotherapy. Eight participants (pembrolizumab, n = 6; placebo, n = 2) died ≤30 days after surgery from surgery-related adverse events. CONCLUSIONS: Neoadjuvant pembrolizumab did not adversely affect surgical outcomes, was associated with numerically higher R0 resections, and improved EFS vs neoadjuvant chemotherapy in surgically relevant subgroups in early-stage NSCLC.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Liberman M, Jones DR, Wakelee H, et al. Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671. Ann Thorac Surg. 2025. PMID: 41203001. doi:10.1016/j.athoracsur.2025.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。